Application of PLEKHH2 in diagnosis and treatment of pulmonary arterial hypertension

By developing PLEKHH2 gene-related reagents to inhibit the binding of Hic-5 to SMAD7 or upregulate PLEKHH2 expression, the shortcomings of existing technologies in the treatment of pulmonary hypertension have been addressed, providing an effective means of prevention and treatment, reversing pulmonary vascular pathological remodeling, and reducing right ventricular pressure and hypertrophy.

CN118949038AActive Publication Date: 2024-11-15FUWAI HOSPITAL CHINESE ACAD OF MEDICAL SCI & PEKING UNION MEDICAL COLLEGE

Patent Information

Application Number
CN202411066431.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-08-04
Filing Date
2024-08-05
Publication Date
2024-11-15
Estimated Expiration
2044-08-05

AI Technical Summary

Technical Problem

There is a lack of effective treatments to reverse the pathological remodeling of pulmonary hypertension in current technologies. Current drugs can only slow down the progression of the disease but cannot reverse the pathological changes in pulmonary vessels. Furthermore, research on genetically related genes has not yet been applied to the diagnosis and treatment of pulmonary hypertension.

Method used

Using the PLEKHH2 gene and related reagents, drugs for the prevention, treatment, and diagnosis of pulmonary hypertension can be developed by inhibiting the binding of Hic-5 to SMAD7 or upregulating PLEKHH2 expression. These drugs include small molecule compounds, peptides, and antibodies. Gene delivery vectors and protein delivery vectors are used for drug preparation.

Benefits of technology

The PLEKHH2 gene is expressed in pulmonary artery endothelial cells and has the function of protecting pulmonary vessels. It can effectively prevent and treat pulmonary hypertension, providing a new therapeutic target, significantly reducing right ventricular systolic pressure, alleviating right ventricular hypertrophy, and reducing pulmonary artery vascular remodeling.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118949038A_ABST
    Figure CN118949038A_ABST
Patent Text Reader

Abstract

The invention discloses application of PLEKHH2 in diagnosis and treatment of pulmonary arterial hypertension, it is found for the first time that PLEKHH2 is a brand-new genetic related gene of pulmonary arterial hypertension, up-regulation of expression of the PLEKHH2 gene can effectively prevent and reverse pulmonary arterial hypertension, a new therapeutic target is provided for treatment of pulmonary arterial hypertension, and the PLEKHH2 gene has important clinical application value and can be applied to diagnosis and treatment of pulmonary arterial hypertension. In addition, inhibition of combination of Hic-5 and SMAD7 or inhibition of effectiveness of Hic-5 on pulmonary hypertension treatment is found for the first time, and a new thought and strategy are provided for screening, research and development of pulmonary hypertension treatment drugs.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedicine technology, and in particular, the present invention relates to the application of PLEKHH2 in the diagnosis and treatment of pulmonary hypertension. Background Art

[0002] Pulmonary Arterial Hypertension (PAH) is a type of malignant pulmonary vascular disease characterized by increased pulmonary artery pressure and progressive increase in pulmonary vascular resistance, which often leads to severe right heart failure or even death. Idiopathic pulmonary arterial hypertension (IPAH) and hereditary pulmonary arterial hypertension (HPAH) are the main types of pulmonary arterial hypertension, accounting for 37%-49% of the first type of pulmonary arterial hypertension. IPAH / HPAH is a rare disease with an incidence of 5-10 per million people. IPAH / HPAH can occur in all age groups from children to adults. The main clinical problem facing IPAH / HPAH is the lack of truly effective therapeutic drugs. Existing drugs for the treatment of pulmonary arterial hypertension are all "symptomatic treatments" that dilate pulmonary blood vessels, which can only delay the progression of the disease, and there is no drug that can effectively reverse the pathological remodeling of the patient's pulmonary vascular remodeling. The significant disease burden of IPAH / HPAH has attracted great attention at the national level. In 2018, the National Health Commission and five other ministries included IPAH / HPAH in the "First List of Rare Diseases in China", clearly defining it as an important national rare disease. Therefore, it is urgent to further accelerate basic research related to pulmonary arterial hypertension and discover new drug targets.

[0003] IPAH / HPAH is a monogenic autosomal dominant genetic disease with obvious familial inheritance and aggregation. As of December 2022, a total of 21 genetic genes related to pulmonary hypertension have been discovered worldwide (of which BMP9 and PTGIS were originally reported by the research group of the inventor of the present invention), which can generally explain the causes of 50-70% HPAH and 20-40% IPAH patients. Genetically related genes are not only a breakthrough in understanding the cause of pulmonary hypertension patients, but also the key to uncovering the pathological mechanism of pulmonary hypertension and developing new drugs. Most of the currently known pathogenic genes for pulmonary hypertension (BMPR2, ALK1, ENG, CAV1, SOX17, KDR, etc.) are highly expressed in pulmonary vascular endothelial cells, suggesting that pulmonary vascular endothelial cell damage is the source of pulmonary hypertension. Among them, targeting the pulmonary hypertension pathogenic genes BMPR2 and SOX17, upregulating the expression of these genes or increasing their activity can protect pulmonary arterial endothelial cells, inhibit proliferation, and reverse mesenchymal transition. It has shown good effects in preventing or treating pulmonary hypertension in animal models. Some drugs have entered clinical trials and are currently a hot spot in the global research and development of pulmonary hypertension drugs.

[0004] Therefore, the discovery of genetic genes related to pulmonary hypertension has dual clinical significance: on the one hand, pathogenic mutations are the true cause of IPAH / HPAH pulmonary hypertension, which is crucial for clinical disease diagnosis; on the other hand, if it is clear that the pathogenic gene has a protective effect, the pathogenic gene will become a new potential target, providing new possibilities for clinical treatment. In view of this, the present invention adopts the strategy of "genetic family discovery-sporadic patient verification" to first discover that PLEKHH2 is a new genetic gene related to pulmonary hypertension. Cell experiments show that the PLEKHH2 gene has an important protective effect on pulmonary vascular endothelial cells, and animal experiments confirm that high expression of PLEKHH2 can effectively prevent and treat pulmonary hypertension. So far, there has been no relevant research or report on the application of PLEKHH2 in the diagnosis and / or treatment of pulmonary hypertension. Summary of the invention

[0005] In view of the technical problems existing in the prior art, the purpose of the present invention is to provide an application of PLEKHH2 in the diagnosis and treatment of pulmonary hypertension.

[0006] In order to achieve the above object, the present invention adopts the following technical solutions:

[0007] The first aspect of the present invention provides an agent that inhibits the binding of Hic-5 to SMAD7 and / or the use of an agent that inhibits Hic-5 in the preparation of a medicament for preventing, treating, alleviating and / or improving pulmonary hypertension.

[0008] Further, the reagent includes small molecule compounds, polypeptides, peptide mimetics, nucleic acid molecules, proteins, antibodies, antibody mimetics, fusion proteins, protein analogs, gene delivery vectors, protein delivery vectors, aptamers, shRNA, siRNA, miRNA, antisense nucleic acids, CRISPR gene editing reagents and / or any combination thereof targeting the binding site of Hic-5 and SMAD7 and / or targeting Hic-5;

[0009] Optionally, the Hic-5 and SMAD7 binding site is the LIM3 domain of Hic-5;

[0010] Optionally, the agent is capable of competitively binding with SMAD7 to the LIM3 domain of Hic-5;

[0011] Optionally, the reagent includes PLEKHH2 and / or a PLEKHH2 promoter;

[0012] Optionally, the PLEKHH2 and / or PLEKHH2 promoter includes PLEKHH2 gene, PLEKHH2 mRNA, PLEKHH2 cDNA, PLEKHH2 protein, peptide segment of PLEKHH2 protein, analog of PLEKHH2 protein, active fragment of any of the foregoing, vector expressing PLEKHH2, nanoparticles carrying PLEKHH2 gene, viral vector carrying PLEKHH2 gene, PEG-modified protein encapsulating PLEKHH2 gene or protein, protein microspheres encapsulating PLEKHH2 gene or protein, liposomes encapsulating PLEKHH2 gene or protein, extracellular vesicles encapsulating PLEKHH2 gene or protein and / or any combination thereof;

[0013] Optionally, the PLEKHH2 and / or PLEKHH2 promoter prevents, treats, alleviates and / or improves pulmonary arterial hypertension by inhibiting SMAD2 / 3 hyperphosphorylation.

[0014] In the present invention, the present invention experimentally verifies for the first time the effectiveness of inhibiting the binding of Hic-5 to SMAD7 and / or inhibiting Hic-5 in preventing, treating, alleviating and / or improving pulmonary hypertension.

[0015] The second aspect of the present invention provides the use of PLEKHH2 and / or a PLEKHH2 promoter in the preparation of a medicament for preventing, treating, alleviating and / or improving pulmonary hypertension.

[0016] Further, the PLEKHH2 includes PLEKHH2 gene, PLEKHH2 mRNA, PLEKHH2 cDNA, PLEKHH2 protein, active fragments of any of the foregoing, and / or any combination thereof;

[0017] Optionally, the PLEKHH2 promoter includes a substance that increases the level of PLEKHH2, a substance that enhances the activity of PLEKHH2, a substance that delays the metabolism of PLEKHH2, and / or any combination thereof;

[0018] Optionally, the PLEKHH2 promoter includes a natural purified substance, a modified natural purified substance, a semi-synthetic substance and / or a chemically synthesized substance;

[0019] Optionally, the PLEKHH2 promoter includes PLEKHH2 protein, a peptide fragment of PLEKHH2 protein, an analog of PLEKHH2 protein, a vector expressing PLEKHH2, nanoparticles carrying the PLEKHH2 gene, a viral vector carrying the PLEKHH2 gene, a PEG-modified protein encapsulating the PLEKHH2 gene or protein, a protein microsphere encapsulating the PLEKHH2 gene or protein, a liposome encapsulating the PLEKHH2 gene or protein, an extracellular vesicle encapsulating the PLEKHH2 gene or protein, and / or any combination thereof.

[0020] Optionally, the PLEKHH2 and / or PLEKHH2 promoter can reduce right ventricular systolic pressure, alleviate right ventricular hypertrophy, increase tricuspid annular systolic displacement, and alleviate pulmonary artery vascular remodeling.

[0021] In some embodiments, the PLEKHH2 includes a PLEKHH2 gene and a PLEKHH2 protein. The PLEKHH2 gene is transcribed and translated into a PLEKHH2 protein product in the subject. In a preferred embodiment, the Gene ID of the PLEKHH2 gene is 130271, and its full name is pleckstrin homology, MyTH4 and FERM domain containing H2 [Homo sapiens (human)]. The Hic-5 is also known as TGFB1I1, and its corresponding Gene ID in NCBI (https: / / www.ncbi.nlm.nih.gov / ) is 7041. The Gene ID corresponding to the SMAD7 in NCBI is 4092.

[0022] In some embodiments, the PLEKHH2 is from a mammal, including but not limited to: humans, non-human primates (e.g., gorillas, apes, monkeys), rodents (e.g., rats, mice, guinea pigs), pets (e.g., cats, dogs), livestock (e.g., horses, cows, sheep, pigs, rabbits). In a preferred embodiment, the PLEKHH2 is from a human.

[0023] In some embodiments, the PLEKHH2 has a sequence known in the art or is a derivative molecule thereof. In some embodiments, the PLEKHH2 is a molecule comprising the following sequence: (a) a PLEKHH2 molecule having a sequence such as Gene ID: 130271 (human), Gene ID: 213556 (rat), Gene ID: 313866 (Norway rat), Gene ID: 713488 (rhesus monkey), Gene ID: 100299044 (cattle); (b) a molecule hybridizing with the sequence defined in (a) under stringent conditions; (c) a molecule having a sequence homology of more than 70% (e.g., 75%, 80%, 85%, 90%, 95%, 98%, 99%, 99.5% or more, or any value or range of values ​​therebetween) with the sequence of the molecule shown in (a) or (b), such as a PLEKHH2 molecule obtained by codon optimization.

[0024] In some embodiments, the PLEKHH2 promoter refers to a substance that can increase the level of PLEKHH2, enhance the activity of PLEKHH2 and / or delay the metabolism of PLEKHH2, including but not limited to: small molecule compounds, vectors expressing PLEKHH2, nanoparticles carrying the PLEKHH2 gene, viral vectors carrying the PLEKHH2 gene, PEG-modified proteins encapsulating the PLEKHH2 gene or protein, protein microspheres encapsulating the PLEKHH2 gene or protein, liposomes encapsulating the PLEKHH2 gene or protein, extracellular vesicles encapsulating the PLEKHH2 gene or protein and / or any combination thereof.

[0025] In some embodiments, the vector includes, but is not limited to, lentiviral vectors, retroviral vectors, poxvirus vectors, herpes simplex virus vectors, adenovirus vectors, adeno-associated virus vectors, DNA plasmid vectors, liposomes bound to DNA plasmids, molecular couples bound to DNA plasmids and / or polymers bound to DNA plasmids. As long as the vector can be used to deliver the target gene PLEKHH2 described in the present invention, it is within the protection scope of the present invention. In a preferred embodiment, the vector is an adenovirus vector.

[0026] The third aspect of the present invention provides any of the following products:

[0027] (1) A pharmaceutical composition for preventing, treating, alleviating and / or improving pulmonary arterial hypertension, the pharmaceutical composition comprising the agent for inhibiting the binding of Hic-5 to SMAD7 and / or the agent for inhibiting Hic-5 described in the first aspect of the present invention, and / or the PLEKHH2 and / or PLEKHH2 promoter described in the second aspect of the present invention;

[0028] (2) A pharmaceutical preparation for preventing, treating, alleviating and / or improving pulmonary hypertension, comprising the pharmaceutical composition.

[0029] Furthermore, the pharmaceutical composition may also contain other drugs for preventing, treating, alleviating and / or improving pulmonary hypertension; optionally, the drugs include calcium channel blockers, prostacyclin drugs, endothelin receptor antagonists, phosphodiesterase-5 inhibitors and / or guanylate cyclase agonists; optionally, the pharmaceutical composition may also contain pharmaceutically acceptable carriers and / or excipients;

[0030] Optionally, the dosage form of the pharmaceutical preparation includes injection, lyophilized powder, solution, tablet, capsule, granule, ointment, cream, gel, suspension, oral solution, controlled release dosage form, nanocrystal preparation, microemulsion and / or solid dispersion.

[0031] In some embodiments, other drugs for preventing, treating, alleviating and / or improving pulmonary arterial hypertension contained in the pharmaceutical composition include but are not limited to: calcium channel blockers, prostacyclin drugs, endothelin receptor antagonists, phosphodiesterase-5 inhibitors and / or guanylate cyclase agonists. As long as the drugs can be used for preventing, treating, alleviating and / or improving pulmonary arterial hypertension, they are within the protection scope of the present invention. In some embodiments, the calcium channel blockers include but are not limited to diltiazem, verapamil, nifedipine, amlodipine, nitrendipine, felodipine, and lercanidipine; the prostacyclin drugs include but are not limited to rioprost, abaprost, dinoprostone, cyprostatin, enprost, trimoprost, and roxaprostol; the endothelin receptor antagonists include but are not limited to bosentan, ambrisentan, and macitentan; the phosphodiesterase-5 inhibitors include but are not limited to tadalafil, vardenafil, and sildenafil; the guanylate cyclase agonists include but are not limited to rioxiguanide, beraprost, vericiguat, and linaclotide.

[0032] In some embodiments, specific illustrative examples of the pharmaceutically acceptable carriers and / or excipients include, but are not limited to: sugars, such as lactose, glucose and sucrose; starches, such as corn starch and potato starch; cellulose and its derivatives, such as sodium carboxymethylcellulose, ethyl cellulose and methyl cellulose; tragacanth powder; malt; gelatin; talc; solid lubricants, such as stearic acid and magnesium stearate; calcium sulfate; vegetable oils, such as peanut oil, cottonseed oil, sesame oil, olive oil, corn oil and cocoa butter; polyols, such as propylene glycol, glycerol, sorbitol, mannitol and polyethylene glycol; alginic acid; emulsifiers, such as wetting agents, such as sodium lauryl sulfate; colorants; flavorings; tableting agents, stabilizers; antioxidants; preservatives; pyrogen-free water; isotonic saline solution; and phosphate buffer, etc.

[0033] In some embodiments, suitable pharmaceutically acceptable carriers and / or excipients are described in detail in Remington's Pharmaceutical Sciences (19th ed., 1995). These substances are used to help the stability of the formulation or to help improve the activity or its biological effectiveness or to produce an acceptable taste or smell in the case of oral administration as needed. The preparations that can be used in such pharmaceutical compositions can be in the form of the original compound itself, or optionally in the form of a pharmaceutically acceptable salt thereof. The pharmaceutical composition thus prepared can be administered in any appropriate manner known to those skilled in the art as needed. When using the pharmaceutical composition, a safe and effective amount of the pharmaceutical composition of the present invention is administered to a human.

[0034] In some embodiments, the suitable dosage of the pharmaceutical composition described in the present invention can be prescribed in a variety of ways according to factors such as the formulation method, administration method, patient's age, weight, sex, morbidity, diet, administration time, administration route, excretion rate and reaction sensitivity. A skilled physician can usually easily determine the prescription and the dosage that is effective for the desired prevention and / or treatment.

[0035] A fourth aspect of the present invention provides any of the following applications:

[0036] (1) Application of the LIM3 domain of Hic-5 in screening candidate drugs for preventing, treating, alleviating and / or improving pulmonary arterial hypertension;

[0037] (2) Use of PLEKHH2 and / or Hic-5 in screening candidate drugs for preventing, treating, alleviating and / or improving pulmonary arterial hypertension;

[0038] (3) Application of Hic-5 and / or SMAD7 in screening candidate drugs for preventing, treating, alleviating and / or improving pulmonary arterial hypertension;

[0039] (4) Use of SMAD7 in the preparation of a drug for preventing, treating, alleviating and / or improving pulmonary arterial hypertension;

[0040] (5) Use of a reagent for detecting the expression level of PLEKHH2 in a sample in the preparation of a product for diagnosing and / or assisting in the diagnosis of pulmonary arterial hypertension.

[0041] Further, the reagents include a reagent for detecting the expression level of PLEKHH2 mRNA in a sample and a reagent for detecting the expression level of PLEKHH2 protein in a sample; optionally, the reagent for detecting the expression level of PLEKHH2 mRNA in a sample includes a primer for specifically amplifying PLEKHH2 and / or a probe for specifically recognizing PLEKHH2; optionally, the reagent for detecting the expression level of PLEKHH2 protein in a sample includes a binding agent that specifically binds to a protein encoded by PLEKHH2; optionally, the binding agent includes an antibody, an antibody functional fragment, an agglutinating agent, a receptor and / or a coupled antibody that specifically binds to a protein encoded by PLEKHH2.

[0042] In some embodiments, the sample refers to a composition obtained from or derived from a target subject, which contains cell entities and / or other molecular entities to be characterized and / or identified, for example, based on physical, biochemical, chemical and / or physiological characteristics. The sample can be obtained from the subject's blood and other fluid samples and tissue samples of biological origin, such as biopsy tissue samples or tissue cultures or cells derived therefrom. The source of the tissue sample can be a solid tissue, such as an organ or tissue sample, a biopsy tissue or an aspirate from fresh, frozen and / or preserved; blood or any blood component; body fluid; cells from any time of individual pregnancy or development; or plasma. The term sample includes biological samples that have been processed in any way after it is obtained, such as reagent treatment, stabilization, or enrichment for certain components (such as proteins or polynucleotides), or embedded in a semi-solid or solid matrix for sectioning purposes. The sample described in the present invention includes, but is not limited to, blood, tissue, blood-derived cells, serum, plasma, lymph, synovial fluid, cell extracts, and combinations thereof. In a preferred embodiment, the sample is selected from the subject's blood or tissue.

[0043] In some embodiments, the binding agent that specifically binds to the protein encoded by PLEKHH2 includes an antibody, an antibody functional fragment, an agglutinating agent, a receptor, a coupled antibody peptide, an aptamer and / or a compound that specifically binds to the PLEKHH2 protein.

[0044] In some embodiments, the reagent is used to detect the expression level of PLEKHH2 in the sample through sequencing technology, nucleic acid hybridization technology, nucleic acid amplification technology, and protein immunoassay technology.

[0045] Furthermore, the method described in the fifth aspect below is used to screen candidate drugs.

[0046] A fifth aspect of the present invention provides any of the following methods:

[0047] (1) A method for screening candidate drugs for preventing, treating, alleviating and / or improving pulmonary hypertension, the method comprising the following steps:

[0048] (a) treating a system expressing or containing the PLEKHH2 gene with a test substance;

[0049] (b) detecting the expression of the PLEKHH2 gene in the system;

[0050] (c) selecting a test substance that can increase the expression level of the PLEKHH2 gene as a candidate drug;

[0051] In some embodiments, any substance that may have a preventive, therapeutic, alleviating and / or improving effect on pulmonary hypertension is a test substance. Further, the test substance selected in step (c) is a test substance that significantly increases the expression level of PLEKHH2 compared to the expression level detected in the absence of the test substance;

[0052] (2) A method for screening candidate drugs for preventing, treating, alleviating and / or improving pulmonary hypertension based on the LIM3 domain of Hic-5, the method comprising the following steps: screening an agent capable of binding to the LIM3 domain of Hic-5 as a candidate drug;

[0053] (3) A method for screening candidate drugs for preventing, treating, alleviating and / or improving pulmonary hypertension based on PLEKHH2 and / or Hic-5, the method comprising the following steps: simulating the binding site of Hic-5 and PLEKHH2, designing and / or screening agents that can bind to the binding site as candidate drugs;

[0054] (4) A method for screening candidate drugs for preventing, treating, alleviating and / or improving pulmonary hypertension based on Hic-5 and / or SMAD7, the method comprising the following steps: simulating the binding site of Hic-5 and SMAD7, and designing and / or screening agents that can bind to the binding site as candidate drugs;

[0055] Optionally, the system includes a cell system, a subcellular system, a solution system, a tissue system, an organ system and / or an animal system; optionally, the substance to be tested includes a substance that increases the level of PLEKHH2, a substance that enhances the activity of PLEKHH2, a substance that delays the metabolism of PLEKHH2 and / or any combination thereof; optionally, the reagent includes small molecule compounds, polypeptides, peptide mimetics, nucleic acid molecules, proteins, antibodies, antibody mimetics, fusion proteins, protein analogs, gene delivery vectors, protein delivery vectors, aptamers, shRNA, siRNA, miRNA, antisense nucleic acids, CRISPR gene editing reagents and / or any combination thereof targeting the binding site of Hic-5 and SMAD7 and / or Hic-5.

[0056] A sixth aspect of the present invention provides any of the following products:

[0057] (1) A product for diagnosing and / or assisting in the diagnosis of pulmonary hypertension, the product comprising the reagent described in the fourth aspect of the present invention;

[0058] (2) A system / device for diagnosing and / or assisting in the diagnosis of pulmonary hypertension, the system / device comprising a processor, an input module, and an output module;

[0059] The processor is used to perform logical operations on the input information using bioinformatics methods; the input module is used to input the expression level of PLEKHH2 in the subject sample, and contains a computer-readable medium of instructions, which, when executed by the processor, executes an algorithm on the input expression level of PLEKHH2; the output module is used to output whether the subject suffers from pulmonary hypertension or the risk of suffering from pulmonary hypertension;

[0060] Optionally, the product further comprises a reagent for detecting the expression level of PLEKHH2 in a sample by sequencing technology, nucleic acid hybridization technology, nucleic acid amplification technology and / or protein immunoassay technology;

[0061] Optionally, the product includes a kit, a chip and / or a test strip.

[0062] Further, the kit includes an RT-PCR kit, a DNA chip kit, an ELISA kit, a protein chip kit, a rapid detection kit or an MRM (multiple reaction monitoring) kit; in some embodiments, the kit may further include elements necessary for reverse transcription polymerase chain reaction. The RT-PCR kit includes a pair of primers specific for a gene encoding a marker protein. Each primer is a nucleotide with a nucleic acid sequence specific for the gene, and its length may be about 7 to 50 bp, more particularly about 10-39 bp. In addition, the kit may further include primers specific for the nucleic acid sequence of a control gene. In some embodiments, the RT-PCR kit may also include a test tube or suitable vessel, a reaction buffer (different pH values ​​and magnesium concentrations), deoxynucleotides (dNTPs), enzymes (e.g., Taq polymerase and reverse transcriptase), deoxyribonuclease inhibitors, ribonuclease inhibitors, DEPC-water and sterile water. In some embodiments, the kit may include elements necessary for operating a DNA chip. The DNA chip kit may include a substrate bound to a gene or cDNA or an oligonucleotide equivalent to a fragment thereof, and reagents, agents and enzymes for constructing a fluorescently labeled probe. In addition, the substrate may include a control gene or cDNA or an oligonucleotide equivalent to a fragment thereof. In some embodiments, the kit disclosed in the present invention may include elements necessary for performing ELISA. The ELISA kit may include antibodies specific for a protein (the biomarker PLEKHH2 protein of the present invention). The antibody has high selectivity and affinity for the marker protein, has no cross-reactivity with other proteins, and may be a monoclonal antibody, a polyclonal antibody or a recombinant antibody. In addition, the ELISA kit may include antibodies specific for a control protein. In addition, the ELISA kit may further include reagents capable of detecting the bound antibody, for example, a labeled second antibody, a chromophore, an enzyme (e.g., conjugated to an antibody), and a substrate thereof or a substance capable of binding the antibody.

[0063] In addition, the present invention also provides a method for preventing, treating, alleviating and / or improving pulmonary hypertension. The method comprises the following steps: administering an effective amount of the present invention as described above to a subject in need thereof, the reagent for inhibiting the binding of Hic-5 to SMAD7 and / or the reagent for inhibiting Hic-5, PLEKHH2 and / or PLEKHH2 promoter, pharmaceutical composition and / or pharmaceutical preparation.

[0064] In addition, the present invention also provides a method for diagnosing and / or assisting in the diagnosis of pulmonary hypertension. The method comprises the following steps: detecting the expression level of PLEKHH2 in a sample derived from a subject, and if the expression level of PLEKHH2 in the sample derived from the subject is significantly lower than that of a normal person, the subject is diagnosed as a patient with pulmonary hypertension.

[0065] In some embodiments, the subject refers to any animal, and also refers to humans and non-human animals. The term non-human animals includes all vertebrates, for example, mammals, such as non-human primates (particularly higher primates), sheep, dogs, rodents (such as mice or rats), guinea pigs, goats, pigs, cats, rabbits, cattle, and any livestock or pets; and non-mammals, such as chickens, amphibians, reptiles, etc. In a specific embodiment of the present invention, the subject is preferably a human.

[0066] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those of ordinary skill in the art to which the present invention belongs. In order to facilitate understanding of the present invention, the following terms involved in the present invention are explained here:

[0067] As used herein, the terms “include” or “comprising” refer to including any one or more of the stated elements or components but do not exclude other elements or components.

[0068] As used herein, the term "expression level" is the same as "level", which refers to the absolute amount or relative amount of the biomarker PLEKHH2 in the present invention. The expression level of the biomarker PLEKHH2 in the present invention can be determined by a variety of techniques. In particular, the absolute amount or relative amount of the biomarker PLEKHH2 in the present invention can be detected by methods well known to those skilled in the art.

[0069] As used herein, the term "primer" refers to a 7-50 nucleic acid sequence that can form a base pair complementary to a template strand and acts as a starting point for replicating the template strand. Primers are usually synthesized, but naturally occurring nucleic acids can also be used. The sequence of the primer does not necessarily need to be exactly the same as that of the template, as long as it is sufficiently complementary and can hybridize with the template. Additional features that do not change the basic properties of the primer can be mixed in. Examples of additional features that can be mixed in include methylation, capping, replacement of more than one nucleic acid by a homolog, and modification between nucleic acids, but are not limited thereto.

[0070] As used herein, the term "probe" refers to a nucleic acid fragment as short as a few to as long as hundreds of bases, such as RNA or DNA, which can establish specific binding with mRNA and can determine the presence of specific mRNA due to labeling. The probe can be prepared in the form of oligonucleotide probes, single-stranded DNA probes, double-stranded DNA probes, and RNA probes.

[0071] As used herein, the term "antibody" refers to a specific immunoglobulin for an antigenic site. The antibody in the present invention refers to an antibody that specifically binds to the PLEKHH2 protein of the present invention, and the antibody can be manufactured according to conventional methods in the art. The form of the antibody includes polyclonal antibodies or monoclonal antibodies, antibody fragments (such as Fab, Fab', F(ab')2 and Fv fragments), single-chain Fv (scFv) antibodies, multispecific antibodies (such as bispecific antibodies), monospecific antibodies, monovalent antibodies, chimeric antibodies, humanized antibodies, human antibodies, fusion proteins comprising an antigen binding site of an antibody, and any other modified immunoglobulin molecules comprising an antigen binding site, as long as the antibody exhibits the desired biological binding activity.

[0072] As used herein, the term "peptide" refers to a class of substances that have the ability to highly bind to a target substance (biomarker protein of the present invention) and do not denature during heat or chemical treatment. Moreover, due to its small size, it can be used as a fusion protein by attaching it to other proteins. Specifically, because it can be specifically attached to a polymer protein chain, it can be used as a diagnostic kit and a drug delivery substance.

[0073] As used herein, the term "aptamer" refers to a polynucleotide composed of a specific type of single-stranded nucleic acid (DNA, RNA or modified nucleic acid), which has a stable tertiary structure and has the property of being able to bind to a target molecule (the biomarker protein of the present invention) with high affinity and specificity. As described above, since aptamers can specifically bind to antigenic substances like antibodies, but are more stable than proteins and have a simple structure, and are composed of polynucleotides that are easy to synthesize, they can be used instead of antibodies.

[0074] As used herein, the term "biomarker" is the same as "marker", and refers to an indicator of the phenotype of a patient (specifically a patient with pulmonary hypertension in the present invention), such as an indicator of a pathological state or possible responsiveness to a therapeutic agent, which can be detected in a biological sample of the patient. The biomarker includes but is not limited to: DNA, RNA, protein, small molecule metabolites, carbohydrates, glycolipid-based molecules, etc.; in a specific embodiment of the present invention, the biomarker is PLEKHH2.

[0075] As used herein, the term "treatment" generally refers to treatment of humans or animals (e.g., used by veterinarians) where some desired therapeutic effect can be achieved, such as inhibiting the development of a disease (including reducing the rate of development, stopping the development), improving the disease, and curing the disease. Treatment as a preventive measure (e.g., prevention) is also included. Use in patients who have not yet developed a disease but are at risk of developing the disease is also included in the term "treatment."

[0076] As used herein, the term "diagnosis" refers to the discovery, judgment or recognition of an individual's health status or condition based on one or more symptoms, data or other information related to the individual. The individual's health status can be diagnosed as healthy / normal (i.e., the absence of disease or illness), or can be diagnosed as unhealthy / abnormal (i.e., the presence of disease or illness). The terms diagnosis, early diagnosis, diagnosis and variations of these terms include early discovery of diseases / disorders associated with specific diseases or illnesses (specifically pulmonary hypertension in the present invention); characteristics or classification of the disease; discovery of the progression, cure or recurrence of the disease; discovery of the individual's response to the disease after treatment or treatment. In the present invention, the diagnosis and / or auxiliary diagnosis of pulmonary hypertension includes distinguishing between individuals who do not suffer from pulmonary hypertension and individuals who suffer from pulmonary hypertension.

[0077] As used herein, the term "pharmaceutical composition" may have any formulation selected from the following: tablets, pills, powders, granules, capsules, suspensions, solutions, emulsions, syrups, sterile aqueous solutions, non-aqueous solutions, lyophilized preparations, and suppositories. In addition, the pharmaceutical composition may be administered once or multiple times. In this case, the pharmaceutical composition may be administered in the form of a liquid preparation, powder, aerosol, capsule, or suppository.

[0078] The administration route of the pharmaceutical composition includes, but is not limited to, intraperitoneal, intravenous, intramuscular, subcutaneous, intradermal, oral, topical, intranasal, intrapulmonary, rectal, etc. When administered orally, a coating that protects the active ingredient in the pharmaceutical composition to prevent degradation in the stomach can be formulated. In addition, the active ingredient can be administered by any device that can be transferred to the target tissue. In a specific embodiment, the pharmaceutical composition provided by the present invention can be made into various dosage forms according to actual needs, and can be administered by a clinician according to factors such as the type, age, weight and general disease condition of the subject, and the mode of administration to determine the dosage that is beneficial to the patient. The mode of administration can, for example, be injection or any other suitable mode of administration known to those skilled in the art.

[0079] As used herein, the term "effective amount" refers to an amount that has a therapeutic effect or an amount required to produce a therapeutic effect in a subject. For example, a therapeutically or pharmaceutically effective amount refers to the amount of a drug required to produce the desired therapeutic effect, and the therapeutic effect can be reflected by the results of clinical trials, model animal studies, and / or in vitro studies. The pharmaceutically effective amount depends on several factors, including but not limited to: characteristic factors of the subject (such as height, weight, sex, age, and medication history), the severity of the disease, etc.

[0080] Compared with the prior art, the present invention has the following advantages and beneficial effects:

[0081] (1) The present invention adopts the strategy of "genetic family discovery-sporadic patient verification" to discover for the first time that PLEKHH2 is a new genetic gene related to pulmonary arterial hypertension. The results of gene function studies show that PLEKHH2 is specifically expressed in pulmonary arterial endothelial cells and has the potential to regulate the activity of the BMPR2 / TGF-β pathway and protect pulmonary arterial endothelial cells. In addition, the present invention finds that the PELKHH2 gene is significantly downregulated under the pathological conditions of pulmonary arterial hypertension. In an animal model of pulmonary arterial hypertension, upregulating the expression of the PLEKHH2 gene using adenovirus can effectively prevent and reverse monocrotaline (MCT)-induced pulmonary arterial hypertension, confirming the effectiveness of PLEKHH2 in preventing, treating and / or diagnosing pulmonary arterial hypertension, providing a new therapeutic target for the treatment of pulmonary arterial hypertension, and having important clinical application value.

[0082] (2) The present invention first discovered that PLEKHH2 and SMAD7 competitively bind to Hic-5 protein in lung tissue. Under the pathological condition of pulmonary hypertension, PLEKHH2 protein mutates or its expression level decreases, and Hic-5 captures more SMAD7, preventing SMAD7 from inhibiting SMAD2 / 3 activity, thereby enhancing the activity of the SAMD2 / 3 signaling pathway, promoting excessive proliferation of endothelial cells, accelerating the phenotype transition of endothelial cells to mesenchymal cells, and ultimately leading to pulmonary hypertension. Upregulating PLEKHH2 expression can prevent Hic-5 from binding to SMAD7, allowing more SMAD7 to be released into the cytoplasm, inhibiting SMAD2 / 3 phosphorylation, and thus treating pulmonary hypertension.

[0083] (3) Based on previous research results, this project further clarified the molecular mechanism of PLEKHH2 in protecting pulmonary vascular remodeling, and proposed and verified several new ideas for the treatment of pulmonary arterial hypertension:

[0084] 1) The research results of the present invention show that Hic-5 is highly expressed in the case of pulmonary hypertension, capturing more SMAD7 protein and preventing it from inhibiting the function of SMAD2 / 3. Therefore, degradation of Hic-5 is a potential strategy for treating pulmonary hypertension.

[0085] 2) Designing small molecule compounds that simulate the binding site of Hic-5 and PLEKHH2 to reduce the binding of Hic-5 and SMAD7 will be the research and development direction of new drugs. BRIEF DESCRIPTION OF THE DRAWINGS

[0086] Figure 1 To find out that 6 of 10 familial pulmonary hypertension families carry known pathogenic gene mutations;

[0087] Figure 2 The genetic pedigree diagram shows that PLEKHH2 is a new potential pathogenic gene of pulmonary hypertension through two hereditary pulmonary hypertension families, among which W / W: wild type, I1235T / W and S658F / W: both are PLEKHH2 heterozygous mutations;

[0088] Figure 3 The expression results of PLEKHH2 gene in various tissues in NCBI database, among which, Figure A: the expression level of PLEKHH2 in various tissues of adults, Figure B: the expression level of PLEKHH2 in various tissues of developmental stages;

[0089] Figure 4 This is the result of qPCR detection of the expression level of PLEKHH2 gene in multiple organ tissues of rats;

[0090] Figure 5 This is the main localization result of PLEKHH2 shown by immunofluorescence, where blue is DAPI-stained nuclei, red is VWF, showing endothelial cells, and green is PLEKHH2 protein;

[0091] Figure 6 The results of Western blot detection of PLEKHH2 protein expression levels in pulmonary artery smooth muscle cells (PASMC), micropulmonary artery endothelial cells (PMEC), and pulmonary artery endothelial cells (PAEC), among which, Figure A: Western blot results, Figure B: PLEKHH2 protein expression level statistics, *: P<0.05, **: P<0.01, n=3;

[0092] Figure 7The results of the expression of PLEKHH2 gene in the lung tissue of rats with pulmonary hypertension induced by monocrotaline, wherein, Figure A: Statistical graph of mean pulmonary artery pressure (mPAP) of wild control rat group (WT group) and PAH rat model group (MCT group) constructed by subcutaneous injection of 60 mg / kg monocrotaline (MCT) in rats, Figure B: Statistical graph of right ventricular hypertrophy index (RV / (LV+S)) of WT group and MCT group, Figure C: Result graph of mRNA expression level of PLEKHH2 gene in WT group and MCT group, Figure D: Western blot result graph and statistical graph, **: P<0.01, ***: P<0.001, ****: P<0.0001vs WT group, n=5;

[0093] Figure 8 The results of the expression of PLEKHH2 gene in lung tissue of rats with pulmonary hypertension induced by hypoxia + Sugen stimulation are shown in Figure A: statistical graph of mean pulmonary artery pressure (mPAP) of wild control rat group (WT group) and PAH rat model group (Su+Hx group) constructed by subcutaneous injection of Su-5416 (20 mg / kg) for 3 weeks of hypoxia and 2 weeks of reoxygenation, Figure B: statistical graph of right ventricular hypertrophy index (RV / (LV+S)) of WT group and Su+Hx group, Figure C: result graph of mRNA expression level of PLEKHH2 gene in WT group and Su+Hx group, Figure D: Western blot result graph and statistical graph, **: P<0.01, ***: P<0.001, ****: P<0.0001vs WT group, n=5;

[0094] Fig. 9 This is the result of immunofluorescence detection of the expression of PLEKHH2 gene in endothelial cells of lung tissues of patients with pulmonary hypertension, where Control: control lung tissues without pulmonary hypertension, PAH: lung tissues of patients with congenital heart disease and severe pulmonary hypertension;

[0095] Fig.10 The results of PLEKHH2 gene expression after siRNA-PLEKHH2 transfection of PAEC cells, where A: Western blot results, B: PLEKHH2 protein expression level statistics, *: P < 0.05 vs si-NC group, n = 3;

[0096] Fig.11The results of the EDU cell proliferation experiment to detect the effect of knocking down the PLEKHH2 gene on the proliferation ability of PAEC cells, wherein, Figure A: EDU staining results, Figure B: Nomo group EDU staining positive statistics, Figure C: Hypo group EDU staining positive statistics, Nomo group: normoxia (20% oxygen concentration), Hypo group: hypoxia (3% oxygen concentration), *: P < 0.05, **: P < 0.01, ***: P < 0.001, ****: P < 0.0001 vs si-NC group, n = 3;

[0097] Fig.12 The results of Western blot detection of the effect of knocking down PLEKHH2 on the expression of Bcl-2 and Bax in PAEC cells under normoxic conditions, wherein, Figure A: Western blot result diagram (Bcl-2), Figure B: Bcl-2 expression level statistical diagram, Figure C: Western blot result diagram (Bax), Figure D: Bax expression level statistical diagram, *: P < 0.05, **: P < 0.01, ***: P < 0.001, ****: P < 0.0001 vs si-NC group, n = 3;

[0098] Fig.13 The results of Matrigel angiogenesis experiment to detect the effect of knocking down PLEKHH2 on the tube-forming ability of PAEC cells under normoxic or hypoxic conditions, where Nomo group: normoxia (20% oxygen concentration), Hypo group: hypoxia (3% oxygen concentration);

[0099] Fig.14 The results of Western blot detection of the expression and phosphorylation changes of key proteins in the BMPR2 / TGF-β pathway in PAEC cells after knocking down the PLEKHH2 gene, wherein, Figure A: Western blot results, Figure B: PLEKHH2 expression level statistics, Figure C: BMPR2 expression level statistics, Figure D: p-SMAD1 / 5 / 8 / SMAD1 / 5 / 8, Figure E: SMAD1 / 5 / 8, Figure F: p-SMAD2 / 3 / SMAD2 / 3, Figure G: ID1, *: P<0.05, **: P<0.01 vs si-NC group, n=1-3;

[0100] Fig.15These are the results that increasing the PLEKHH2 gene in vivo can effectively prevent pulmonary hypertension, where A: Schematic diagram of the experimental design; B-C: The results of the effects of high expression of PLEKHH2 on the right ventricular systolic pressure (RVSP) of MCT-induced rats detected by right cardiac catheterization; D-H: The results of the effects of high expression of PLEKHH2 on the right ventricular structure and function of MCT-induced rats detected by ultrasound, where PAT / PET: pulmonary artery blood flow acceleration time (PAT) / pulmonary artery ejection time (PET), RVOT: right ventricular outflow tract width, TAPSE: tricuspid annular systolic displacement, RVID: right ventricular diameter, RVAW: right ventricular free wall thickness;

[0101] Fig.16 These are the results that increasing the PLEKHH2 gene in vivo can effectively treat pulmonary hypertension, wherein, Figure A: Schematic diagram of the experimental design, Figures B-C: Results of the effects of PLEKHH2 treatment on MCT-induced right ventricular systolic pressure (RVSP) in rats detected by right cardiac catheterization, Figures D-H: Results of the effects of PLEKHH2 treatment on MCT-induced right ventricular structure and function in rats detected by ultrasound, wherein, PAT / PET: pulmonary artery blood flow acceleration time (PAT) / pulmonary artery ejection time (PET), RVOT: right ventricular outflow tract width, TAPSE: tricuspid annular systolic displacement, RVID: right ventricular diameter, RVAW: right ventricular free wall thickness;

[0102] Fig.17 Western blot was used to detect the expression of PLEKHH2, Hic-5 and SMAD7 proteins in the lung tissues of MCT rats, where NC: control group injected with normal saline subcutaneously; MCT: model group injected with 60 mg / kg monocrotaline subcutaneously;

[0103] Fig.18 This is the immunofluorescence staining of pulmonary artery endothelial cells, in which blue: cell nucleus; green: Hic-5; red: PLEKHH2;

[0104] Fig.19 Schematic diagram of the protein structure of PLEKHH2, Hic-5 and SMAD7;

[0105] Fig. 20 To predict the binding ability and binding sites of Hic-5 to SMAD7 and Hic-5 to PLEKHH2 using Alpha-Fold-3 software, Figure A: Green is the MH2 and N-terminal domains of SMAD7 protein, and blue is the full-length Hic-5 protein; Figure B: Green is the full-length Hic-5 protein, blue is the FIRM domain of PLEKHH2, and purple is the protein sequence that Hic-5 directly binds to SMAD7;

[0106] Fig.21 Co-IP was used to detect the binding of PLEKHH2, SMAD7 and Hic-5, where sh-P: knocking down the PLEKHH2 gene using sh-RNA; Ad-P: overexpressing the PLEKHH2 gene using adenovirus; Ad: adenovirus empty vector as control;

[0107] Fig. 22 Co-IP was used to detect the binding of PLEKHH2, SMAD7 and Hic-5 in rat lung tissue after MCT stimulation, where WT: wild-type rats injected with normal saline as a control; WT+MCT: lung tissues were obtained from wild-type rats injected with MCT (40 mg / kg) three weeks later; P-KO+MCT: lung tissues were obtained from PLEKHH2 gene knockout heterozygous rats injected with MCT (40 mg / kg) three weeks later;

[0108] Fig.23 Co-IP was used to detect the binding of PLEKHH2, SMAD7 and Hic-5 in rat lung tissue after hypoxia stimulation, where WT: wild-type rats cultured in normoxia for three weeks as a control; WT+Hypo: lung tissues of wild-type rats were collected after three weeks of chronic hypoxia (10% oxygen concentration); P-KO+Hypo: lung tissues of PLEKHH2 gene knockout heterozygous rats were collected after three weeks of chronic hypoxia (10% oxygen concentration);

[0109] Fig.24 The binding of PLEKHH2, SMAD7 and Hic-5 in the lung tissues of rats with MCT-induced pulmonary hypertension was detected by Co-IP after the expression of PLEKHH2 was increased in vivo. WT: wild-type rats injected with normal saline; WT+MCT: wild-type rats injected with MCT (50 mg / kg) 4 weeks later; Ad-P+MCT: adenovirus prevention group, on the day of MCT injection, the PLEKHH2 gene adenovirus was first administered to the rats through tracheal spray to upregulate the expression of PLEKHH2 gene, and the PLEKHH2 gene adenovirus was administered for the second time at 2 weeks, and the experiment was terminated at 4 weeks.

[0110] Fig.25The Co-IP was used to detect the binding of PLEKHH2, SMAD7 and Hic-5 in the lung tissue of the rat model of pulmonary hypertension induced by hypoxia + Sugen after the expression of PLEKHH2 was increased in vivo, wherein WT: wild-type rats were injected with normal saline and fed with normoxia for 5 weeks; WT+SuHx: disease model group, wild-type rats were subcutaneously injected with Su-5416 (20 mg / kg), and the PAH rat model group was constructed by hypoxia (10% oxygen concentration) for 3 weeks and reoxygenation for 2 weeks; Ad-P+SuHx: prevention group, on the day of subcutaneous injection of Su-5416 in rats, the PLEKHH2 gene adenovirus was first administered to the rats by tracheal spray to upregulate the expression of PLEKHH2 gene, and the PLEKHH2 gene adenovirus was administered for the second time at 3 weeks, and the experiment was terminated at 5 weeks;

[0111] Fig.26 Western blot was used to detect the activation of SMAD2 / 3 in lung tissue of rats with MCT-induced pulmonary hypertension after elevated PLEKHH2 expression in vivo, including: WT: wild-type rats injected with normal saline; WT+MCT: wild-type rats injected with MCT (50 mg / kg) 4 weeks later; Ad-P+MCT: adenovirus prevention group, on the day of MCT injection, the PLEKHH2 gene adenovirus was administered to the rats for the first time through tracheal spray to upregulate PLEKHH2 gene expression, and the PLEKHH2 gene adenovirus was administered for the second time at 2 weeks, and the experiment was terminated at 4 weeks. DETAILED DESCRIPTION

[0112] The present invention is further described below in conjunction with specific embodiments, which are only used to explain the present invention and are not to be construed as limiting the present invention. It will be appreciated by those skilled in the art that various changes, modifications, substitutions and variations may be made to these embodiments without departing from the principles and purposes of the present invention, and that the scope of the present invention is defined by the claims and their equivalents. The experimental methods for which specific conditions are not specified in the following examples are usually tested under conventional conditions or under conditions recommended by the manufacturer.

[0113] Example 1 Collection and study of families with hereditary pulmonary hypertension

[0114] 1. Experimental methods

[0115] From January 2021 to December 2022, a total of 10 families with hereditary pulmonary hypertension were collected in the Genetics Clinic of Fuwai Hospital, Chinese Academy of Medical Sciences. The probands of each family with hereditary pulmonary hypertension were sequenced with whole exome sequencing, and mutations were screened in 21 known pathogenic genes of pulmonary hypertension (ACVRL1, BMPR2, ENG, GDF2, SMAD9, CAV1, ATP13A3, KCNK3, SOX17, EIF2AK4, TBX4, AQP1, SMAD4, SMAD1, KLF2, BMPR1B, KCNA5, ABCC8, KDR, TET2, GGCX).

[0116] The whole exome sequencing method is as follows: DNA was extracted from the whole blood of the subjects using a DNA kit (Qiangen, Germany), and WES was performed according to the standards described in previous studies (see reference 1: Wang XJ, Lian TY, Jiang X, et al. Germline BMP9 mutation causes idiopathic pulmonary arterial hypertension. The European respiratory journal 2019; 53.; reference 2: Tan JS, Yan XX, Wu Y, et al. Rare variants in MTHFR predispose to occurrence and recurrence of pulmonary embolism. International journal of cardiology 2021; 331: 236-42.). A DNA library was constructed using the SureSelect Human All Exon V6 kit and sequenced using the Illumina NovaSeq 6000 system. The average coverage depth of the target region of each sample was >100X, and more than 90% of the target bases were sequenced more than 20 times.

[0117] 2. Experimental results

[0118] The results showed that 6 families carried mutations in genes known to cause pulmonary arterial hypertension (see Figure 1 ), including 4 BMPR2 mutations, 1 TBX4 mutation and 1 ALK1 mutation (see Table 1), with a mutation detection rate of 60%.

[0119] Table 1 Pathogenic gene mutations found in families with hereditary pulmonary hypertension

[0120]

[0121] Among them, NA: PolyPhen2 and SIFT cannot analyze frameshift, nonsense, frameshift deletion, large fragment deletion type and some unexplained gene variations in electronic prediction programs. D: harmful in SIFT, possibly harmful in PolyPhen2, P: possibly harmful.

[0122] Example 2 PLEKHH2 gene mutation is associated with familial pulmonary hypertension

[0123] 1. Experimental methods

[0124] For the four pedigrees in which no pathogenic gene mutations have been found, the present invention performed whole exome sequencing on all core members of pedigrees No. 7 and No. 8 to search for new potential pathogenic genes.

[0125] There are two patients with pulmonary hypertension in family No. 7. The proband is a 42-year-old female. Right cardiac catheterization showed that the mean pulmonary artery pressure was 63 mmHg, the pulmonary vascular resistance was 12.1 Wood Unit, and the acute pulmonary vasodilation test was negative. The proband's second son (21 years old) also had pulmonary hypertension, with a mean pulmonary artery pressure of 87 mmHg, pulmonary vascular resistance of 18.6 Wood Unit, and a negative acute pulmonary vasodilation test. The proband's husband and eldest son are both healthy.

[0126] There are also two patients with pulmonary hypertension in family No. 8. The proband is a female who was diagnosed with pulmonary hypertension at the age of 38, with an average pulmonary artery pressure of 43 mmHg, pulmonary vascular resistance of 5.3 Wood Unit, and negative acute pulmonary vasodilation test. The proband's daughter also has pulmonary hypertension, and the right ventricular systolic pressure was 60 mmHg by ultrasound evaluation at the age of 14. The proband's husband is in good health.

[0127] In this example, whole exome sequencing was performed on a family of four in family 7 and a family of three in family 8, and rare deleterious variants were selected according to the following criteria:

[0128] (1) Co-segregation with the disease phenotype: the variant is shared by both patients but not by the control;

[0129] (2) the variant is located in the exon region or exon-intron splicing region of the gene;

[0130] (3) The mutation type is missense, stop gain, stop loss or small indel, which should affect the amino acid coding;

[0131] (4) The variant frequency MAF in databases such as the 1000 Genomes and GnomAD East Asians is <0.1%;

[0132] (5) At least one of the three bioinformatics software programs, SIFT, PolyPhen-2, and Mutation taster, considers the mutation to be harmful.

[0133] 2. Experimental results

[0134] The results showed that after screening, a total of 61 genes were selected in family 7 and 138 genes were selected in family 8. Taking the intersection of the rare variants of the two families, there were only two genes that appeared repeatedly, namely PLEKHH2 and PKDREJ. Since PKDREJ was not expressed in lung tissue, this gene was excluded, leaving only the PLEKHH2 gene (see Figure 2 ).

[0135] Example 3 Verification of the genetic correlation between PLEKHH2 gene mutation and pulmonary hypertension

[0136] In order to clarify the correlation between PLEKHH2 gene mutation and the onset of pulmonary hypertension, this example selected 176 patients with idiopathic pulmonary hypertension from the Fuwai Hospital of the Chinese Academy of Medical Sciences, and all of them underwent whole exome sequencing. Since all 176 patients were sporadic patients with no family history as a reference, we adopted more stringent standards when evaluating the harmfulness of genetic variation in the PLEKHH2 gene, as follows:

[0137] (1) The mutation is located in the exon region or exon-intron splicing region of the gene;

[0138] (2) The mutation type is missense, stop gain, stop loss or small indel, which should affect the amino acid coding;

[0139] (3) The frequency of the variant should be extremely low, requiring that it is completely absent in the 1000 Genomes Chinese database and that its frequency MAF in the GnomAD East Asian database is less than 1×10 -5 ;

[0140] (4) If it is a missense mutation, all three bioinformatics software, SIFT, PolyPhen-2, and Mutation taster, must consider the mutation to be harmful.

[0141] Using the above criteria, we found 5 new patients carrying rare deleterious mutations in the PLEKHH2 gene, with a mutation rate of 2.8% (5 / 176 = 2.8%). The clinical phenotypes and PLEKHH2 gene mutations of the 5 patients are shown in Table 2. Specifically, the mutations include four missense mutations (c.1624C>T, c.1825G>A, c.2204A>G, c.3718A>T) and one truncating mutation (c.2389C>T), which cause protein sequence changes to: p.P542S, p.A609T, p.Y735C, p.T1240S and p.R797X (premature termination of truncation at amino acid position 797). We checked the PLEKHH2 gene mutations carried by the 5 patients in the 1000 Genomes Chinese population and the GnomAD global population, and found that the frequencies of all mutations were less than 1×10 -5 Or it has never been reported, which is consistent with the genetic characteristics of rare pulmonary arterial hypertension. All four missense mutations were consistently judged to be harmful by three bioinformatics analysis software. We also analyzed the mutations of 21 known pulmonary arterial hypertension pathogenic genes in these five patients and found that they did not carry any known pulmonary arterial hypertension pathogenic gene mutations.

[0142] This example then analyzes the genetic burden of rare PLEKHH2 gene variants on pulmonary hypertension. Using the same criteria as those for screening rare variants in patients with idiopathic pulmonary hypertension, rare PLEKHH2 gene variants were searched in 76,156 controls in the GnomAD database, and 557 variants were found, with a mutation rate of only 0.07%. PLEHKK2 rare variants were significantly more common in patients with pulmonary hypertension (P=0.001, OR=3.1). Thus, the present invention preliminarily clarifies that PLEKHH2 is a new pulmonary hypertension genetically related gene, which is closely related to the onset of pulmonary hypertension.

[0143] Table 2 Genotypes and clinical phenotypes of patients with familial and idiopathic pulmonary hypertension carrying PLEKHH2 gene mutations

[0144]

[0145] Among them, HPAH: hereditary pulmonary arterial hypertension; IPAH: idiopathic pulmonary arterial hypertension; mPAP: mean pulmonary artery pressure; PVR: pulmonary vascular resistance; CO: cardiac output. *: Patient No. 10 is a child, and 13.4 here is the standardized pulmonary vascular resistance (PVRi). Sex: F is female, M is male. MAF in 1000G_CHB: the frequency of this variant in the 1000 Genomes Chinese (387 people). MAF in GnomAD: the frequency of this variant in the GnomAD database (V3.1.1, about 76,156 people).

[0146] Example 4 PLEKHH2 is specifically expressed in pulmonary artery endothelial cells

[0147] The NCBI database shows that the PLEKHH2 gene is highly expressed in lung tissue both in the developmental stage and in the adult stage (see Figure 3 AB). In this example, various organs (heart, lung, liver, spleen, kidney, brain, and skeletal muscle) of 2-month-old wild-type SD rats were taken. In this example, GAPDH was used as an internal reference for relative quantification. The expression of PLEKHH2 in various organs and tissues of the above rats was detected by qPCR. The results showed that the PLEKHH2 gene was highly expressed in lung tissue (see Figure 4 ). Among them, the specific primer sequences used in the qPCR experiment are as follows:

[0148] PLEKHH2 gene:

[0149] The forward primer is 5'-AGCGGACGACTCAAGACT-3' (SEQ ID NO: 1); the reverse primer is 5'-TGAACCGTTTGCT TGTTA-3' (SEQ ID NO: 2);

[0150] GAPDH gene:

[0151] The forward primer was 5'-CTCATGACCACAGTCCATGC-3' (SEQ ID NO: 3); the reverse primer was 5'-CACATTGGGGG TAGGAACAC-3' (SEQ ID NO: 4).

[0152] In this example, immunofluorescence was used to label PLEKHH2 protein in human lung biopsy tissues, and it was found that it was mainly localized in human lung vascular endothelial cells, where blue is DAPI-stained nuclei, red is VWF, showing endothelial cells, and green is PLEKHH2 protein (see Figure 5 In addition, this example cultured three types of human pulmonary vascular structural cells in vitro, including pulmonary artery smooth muscle cells (PASMC), micropulmonary artery endothelial cells (PMEC), and pulmonary artery endothelial cells (PAEC). Western blot was used to detect the expression level of PLEKHH2 protein in the above three types of cells. The results showed that PLEKHH2 protein was highly expressed in the two types of endothelial cells and almost not expressed in smooth muscle cells (see Figure 6 AB). The high expression of PLEKHH2 in lung tissue and its main localization in pulmonary vascular endothelial cells further suggest that it is closely related to pulmonary vascular pathophysiology.

[0153] Example 5 PLEKHH2 expression is significantly reduced under pulmonary hypertension pathological conditions

[0154] 1. Experimental methods

[0155] In order to clarify whether PLEKHH2 is involved in the pathological process of pulmonary hypertension, this example detected the expression of the PLEKHH2 gene in two animal models of pulmonary hypertension.

[0156] Firstly, a PAH rat model (MCT group) was established by subcutaneous injection of 60 mg / kg monocrotaline (MCT) into rats. Three weeks later, the mean pulmonary artery pressure (mPAP) and right ventricular hypertrophy index (RV / (LV+S)) of wild control group rats (WT group) and MCT group rats were detected, and the expression levels of PLEKHH2 gene mRNA and PLEKHH2 protein in lung tissues of wild control group rats and MCT group rats were detected by qPCR and Western blot experiments, respectively.

[0157] Secondly, a PAH rat model (Su+Hx group) was established by subcutaneous injection of Su-5416 (20 mg / kg) into rats, followed by 3 weeks of hypoxia and 2 weeks of reoxygenation. Five weeks later, the mean pulmonary artery pressure (mPAP) and right ventricular hypertrophy index (RV / (LV+S)) of wild-type control group rats (WT group) and Su+Hx group rats were detected, and the expression levels of PLEKHH2 gene mRNA and PLEKHH2 protein in the lung tissues of wild-type control group rats and Su+Hx group rats were detected by qPCR and Western blot experiments, respectively.

[0158] Finally, this example further collected lung tissues from patients with congenital heart disease and severe pulmonary hypertension and control lung tissues without pulmonary hypertension, and detected the expression of PLEKHH2 gene in endothelial cells of lung tissues of patients with pulmonary hypertension by immunofluorescence.

[0159] 2. Experimental results

[0160] The results showed that the expression of PLEKHH2 gene in the lung tissue of rats with pulmonary hypertension induced by monocrotaline or rats with pulmonary hypertension induced by hypoxia + Sugen was significantly reduced. Compared with wild-type control rats, the mean pulmonary artery pressure and right ventricular hypertrophy index of rats with pulmonary hypertension induced by monocrotaline were significantly increased (see Figure 7 AB), the mRNA expression of PLEKHH2 gene decreased by 62% in the MCT group (see Figure 7 C), protein expression decreased by 43% (see Figure 7 D), the difference was extremely significant; compared with wild-type control rats, the mean pulmonary artery pressure and right ventricular hypertrophy index of rats with pulmonary hypertension induced by hypoxia + Sugen stimulation were significantly increased (see Figure 8AB), the mRNA expression of PLEKHH2 gene decreased by 76% in the hypoxia + Sugen group (see Figure 8 C), protein expression decreased by 50% (see Figure 8 D), the difference is extremely significant. Further, this example found that PLEKHH2 was also significantly reduced in lung tissue biopsies of patients with pulmonary hypertension (see Fig. 9 ), suggesting that this gene is closely related to the pathological remodeling of pulmonary hypertension.

[0161] Example 6 Knockdown of PLEKHH2 gene causes pulmonary artery endothelial cells to undergo mesenchymal (EndoMT) phenotype transition

[0162] 1. Experimental methods

[0163] Since the PLEKHH2 gene is significantly decreased under the pathological condition of pulmonary hypertension, this example selects PAEC with the highest background expression of PLEKHH2 protein as the model cell, knocks down PLEKHH2 protein by siRNA, and studies the effect of PLEKHH2 on endothelial cell phenotype.

[0164] First, this embodiment designs and synthesizes two siRNAs with different sequences for the target gene PLEKHH2, namely siRNA-1 and siRNA-2, and then transfects the siRNA into PAEC cells and detects the expression level of PLEKHH2 protein in the transfected PAEC cells by Western blot experiment. Secondly, this embodiment detects the effect of knocking down the PLEKHH2 gene on the proliferation ability of PAEC cells under normoxic (20% oxygen concentration) conditions (Nomo) and hypoxic (3% oxygen concentration) conditions (Hypo) by EDU cell proliferation experiment. Again, this embodiment detects the effect of knocking down PLEKHH2 on the expression of Bcl-2 and Bax in PAEC cells under normoxic conditions by Western blot experiment. Finally, this embodiment detects the effect of knocking down the PLEKHH2 gene on the ability of PAEC cells to form tubes under normoxic (20% oxygen concentration) conditions (Nomo) and hypoxic (3% oxygen concentration) conditions (Hypo) by Matrigel angiogenesis experiment.

[0165] Wherein, the sequence information of siRNA-1 and siRNA-2 is as follows:

[0166] siRNA-1:

[0167] The sense strand is 5'-GAGGAAAUGAGCAAGAUAUTT-3' (SEQ ID NO: 5); the antisense strand is 5'-AUAUCUUGCUCA UUUCCUCTT-3' (SEQ ID NO: 6);

[0168] siRNA-2:

[0169] The sense strand is 5'-GGCUUCUGAAAGUGAUUAUTT-3' (SEQ ID NO: 7); the antisense strand is 5'-AUAAUCACUUUC AGAAGCCTT-3' (SEQ ID NO: 8).

[0170] 2. Experimental results

[0171] The results showed that after siRNA-PLEKHH2 transfection into PAEC cells, the expression level of PLEKHH2 gene was significantly reduced. The two interference fragments of siRNA-1 and siRNA-2 decreased the expression of PLEKHH2 protein by 40%-50% (see Fig.10 AB). Whether under normoxic (20% oxygen concentration) or hypoxic (3% oxygen concentration) conditions, the proliferation capacity of PAEC cells was significantly increased after knocking down the PLEKHH2 gene (see Fig.11 AC). Western blot analysis of cell proliferation and apoptosis-related pathway proteins showed that decreased PLEKHH2 gene expression led to a significant increase in the anti-apoptotic protein Bcl-2, while decreased pro-apoptotic protein Bax expression (see Fig.12 AD). The results of the endothelial cell tube formation experiment showed that the tube formation ability of the siRNA-1 group that knocked down the PLEKHH2 gene was significantly reduced, and the siRNA-2 group was almost unable to form tubes, whether under normoxic or hypoxic conditions (see Fig.13 ). In summary, knockdown of PLEKHH2 gene can cause PAEC cells to overproliferate, resist apoptosis, and be difficult to form tubes, resulting in a significant endothelial-mesenchymal transition (EndoMT) phenotype.

[0172] Example 7 Knockdown of PLEKHH2 gene significantly reduced the activity of BMPR2 pathway in endothelial cells

[0173] 1. Experimental methods

[0174] In order to verify the relationship between PLEKHH2 and the BMPR2 / TGF-β pathway, this example uses Western blot to detect changes in BMPR2 / TGF-β pathway activity after knocking down PLEKHH2 in endothelial cells (PAEC cells), including detection of changes in expression and phosphorylation of key proteins in the BMPR2 / TGF-β pathway (BMPR2, P-SMAD1 / 5 / 8, SMAD1 / 5 / 8, P-SMAD2 / 3, SMAD2 / 3, ID1). In this example, siRNA-2, which has a better effect of knocking down PLEKHH2 in Example 6, is selected to explore the molecular mechanism of action.

[0175] 2. Experimental results

[0176] The results showed that decreased PLEKHH2 expression led to downregulation of BMPR2 expression in endothelial cells, decreased SMAD1 / 5 / 8 phosphorylation, and decreased ID1 expression. On the other hand, SMAD2 / 3 phosphorylation of the TGF-β pathway increased significantly (see Fig.14 AG). Therefore, PLEKHH2 is likely to be a key gene regulating the balance of BMPR2 / TGF-β signaling pathway in endothelial cells. Knocking down PLEKHH2 will lead to weakened BMPR2 signaling and enhanced TGF-β signaling, thereby leading to vascular remodeling in pulmonary hypertension.

[0177] Example 8: Elevating the PLEKHH2 gene in vivo can effectively prevent pulmonary hypertension

[0178] 1. Experimental methods

[0179] PLEKHH2 mutation or reduced expression will promote the occurrence and development of pulmonary hypertension, suggesting that PLEKHH2 itself should be a "good gene" to protect pulmonary blood vessels. This example uses an in vivo animal model to further study whether increasing PLEKHH2 can prevent pulmonary hypertension.

[0180] A rat model of pulmonary hypertension was established by intraperitoneal injection of monocrotaline (MCT, 50 mg / kg) in 8-week-old rats. On the day of MCT injection, the PLEKHH2 gene adenovirus (adenovirus-PLEKHH2) was first administered to the rats by tracheal spray to upregulate the expression of the PLEKHH2 gene. At 10 weeks of age, the PLEKHH2 gene adenovirus (adenovirus-PLEKHH2) was administered for the second time. The experiment was terminated at 12 weeks of age to detect the preventive effect of upregulating the expression of the PLEKHH2 gene on rats with MCT-induced pulmonary hypertension. The specific experimental design diagram is shown in the figure. Fig.15 As shown in A, the control group (control) is adenovirus-vehicle, and the experimental group (case) is adenovirus-PLEKHH2. It is worth noting that the activity of adenovirus can only be maintained for two weeks in rats, so the adenovirus needs to be injected twice within the four-week cycle of this experiment to observe the preventive effect.

[0181] 2. Experimental results

[0182] The results showed that the preventive administration of PLEKHH2 significantly decreased the right ventricular pressure in rats with MCT-induced pulmonary hypertension (see Fig.15 BC), right ventricular wall thickness, right ventricular diameter, and right ventricular outflow tract width were significantly reduced, and the systolic displacement of the tricuspid annulus was significantly increased (see Fig.15 DH), indicating that high expression of PLEKHH2 can effectively prevent MCT-induced pulmonary hypertension.

[0183] Example 9: Elevating the PLEKHH2 gene in vivo can effectively treat pulmonary hypertension

[0184] 1. Experimental methods

[0185] After confirming that high expression of PLEKHH2 has the function of preventing pulmonary hypertension, this example further tests whether PLEKHH2 can treat pulmonary hypertension.

[0186] A rat model of pulmonary hypertension was established by intraperitoneal injection of monocrotaline (MCT, 50 mg / kg) in 8-week-old rats. The pulmonary hypertension of the rats had increased in the second week after MCT injection. PLEKHH2 gene adenovirus (adenovirus-PLEKHH2) was administered into the rats by tracheal spray. The PLEKHH2 gene adenovirus was administered again in the third week. The experiment was terminated in the fourth week to detect the therapeutic effect of up-regulating the expression of the PLEKHH2 gene on rats with MCT-induced pulmonary hypertension. The specific experimental design diagram is shown in the figure. Fig.16 As shown in A, the control group (control) is adenovirus-vehicle, and the experimental group (case) is adenovirus-PLEKHH2.

[0187] 2. Experimental results

[0188] The results showed that the therapeutic administration of PLEKHH2 significantly reduced the pulmonary hypertension that had already occurred in rats with MCT-induced pulmonary hypertension (see 16B-C), the right ventricular wall thickness, right ventricular diameter, and right ventricular outflow tract width were significantly reduced, and the systolic displacement of the tricuspid annulus was significantly increased (see Fig.16 DF), indicating that high expression of PLEKHH2 can effectively treat MCT-induced pulmonary hypertension.

[0189] Example 10 In a rat model of pulmonary hypertension, the expression of PLEKHH2 and SMAD7 is reduced, while the expression of Hic-5 is increased

[0190] The role of Hic-5 and SMAD7 in pulmonary hypertension is currently completely unknown. In order to clarify whether these two proteins are involved in the pathological process of pulmonary hypertension, this example uses conventional methods to construct a classic monocrotaline (MCT)-induced pulmonary hypertension animal model and detect the expression of PLEKHH2, Hic-5 and SMAD7 proteins.

[0191] We constructed a PAH rat model by subcutaneously injecting 60 mg / kg monocrotaline (MCT) into rats (MCT group), and subcutaneously injected normal saline into rats as the control group. After 3 weeks, we collected lung tissues from the control group and the MCT group for Western blot analysis ( Fig.17). The results showed that in the MCT model group, PLEKHH2 protein was significantly reduced (this result is completely consistent with the results in the aforementioned example), Hic-5 expression was increased, and SMAD7 expression was decreased, indicating that these three proteins are involved in vascular remodeling in pulmonary hypertension.

[0192] Example 11 PLEKHH2 and Hic-5 co-localize in pulmonary vascular endothelial cells

[0193] Previous literature reported that PLEKHH2 and Hic-5 co-localize in podocytes (i.e., epithelial cells in the visceral layer of the renal capsule), but it is completely unknown whether they co-localize in pulmonary vascular endothelial cells.

[0194] To this end, we cultured pulmonary artery endothelial cells (PAEC) in vitro and confirmed by immunofluorescence staining that both Hic-5 and PLEKHH2 were highly expressed in PAEC, with their subcellular localization mainly concentrated in the cytoplasm, and their localization was highly overlapped ( Fig.18 ).

[0195] Example 12 Bioinformatics prediction of PLEKHH2 and SMAD7 competitive binding to the LIM3 domain of Hic-5

[0196] Hic-5 protein has 7 main functional domains, including 3 LD domains and 4 LIM domains; SMAD7 has 2 main domains: N-terminal domain and MH2 domain; PLEKHH2 has 5 domains: CC domain, two PH domains, one MyTH domain and one FIRM domain ( Fig.19 ).

[0197] Literature reports that the MH2 and N-terminal domains of SMAD7 protein directly bind to the LIM3 domain (328-380aa) of Hic-5 protein (Oncogene. 2008 November 20; 27(54): 6791–6805). We used Alpha-Fold-3 software to verify the binding ability of the above two protein domains ( Fig. 20 A).

[0198] According to the literature, the FIRM domain of PLEKHH2 can bind to Hic-5 (Kidney International (2012) 82, 1071–1083), but it is not clear which domain of Hic-5 it binds to.

[0199] To this end, we entered the FIRM domain of PLEKHH2 and the full-length protein sequence of Hic-5 into the Alpha-Fold-3 software and found that the FIRM domain of PLEKHH2 also directly binds to the LIM3 domain of Hic-5. Furthermore, we marked the protein sequence of Hic-5 binding to SMAD7 in purple, which is located in the binding area between the FIRM domain of PLEKHH2 and the LIM3 domain of Hic-5 ( Fig. 20 B). This suggests that PLEKHH2 and SMAD7 are likely to bind to the LIM3 region of Hic-5, and there is a competitive binding relationship between the two.

[0200] Example 13 PLEKHH2 and SMAD7 Competitively Bind to Hic-5 at the Cell Level

[0201] To determine whether PLEKHH2 and SMAD7 competitively bind to Hic-5, we cultured pulmonary vascular endothelial cells, knocked down the PLEKHH2 gene using sh-RNA (sh-P), overexpressed the PLEKHH2 gene using adenovirus (Ad-P), and then used Co-IP experiments to determine the changes in the binding of Hic-5 and SMAD7 after changes in PLEKHH2 expression.

[0202] like Fig.21 As shown in Figure 2, sh-RNA indeed knocked down the expression of PLEKHH2 gene in pulmonary vascular endothelial cells and also reduced the binding of PLEKHH2 protein to Hic-5. At this time, the expression level of SMAD7 did not change significantly, but the number of binding to Hic-5 increased significantly. In contrast, after adenovirus overexpressed the PLEKHH2 gene, the number of binding to Hic-5 increased significantly, and the binding of SMAD7 to Hic-5 decreased significantly.

[0203] The above cell experiments clearly show that the binding of PLEKHH2, SMAD7 and Hic-5 proteins is significantly negatively correlated, and there is an obvious competitive relationship between the two.

[0204] Example 14: PLEKHH2 and SMAD7 Competitively Bind to Hic-5 at the Animal Level in Vivo

[0205] To further clarify whether PLEKHH2 and SMAD7 competitively bind to Hic-5 in animals, we constructed a rat model of pulmonary hypertension by subcutaneous injection of monocrotaline and chronic hypoxia, respectively. After the model was successfully established, the rat lung tissue was obtained and the binding of PLEKHH2 and SMAD7 to Hic-5 was detected by Co-IP experiment.

[0206] (1) MCT treatment group

[0207] We set up three groups of rats: 1) wild-type rats injected with saline as control (WT), 2) wild-type rats injected with MCT (40 mg / kg) for three weeks (WT+MCT); 3) PLEKHH2 gene knockout heterozygous rats injected with MCT (40 mg / kg) for three weeks (P-KO+MCT). Total protein in lung tissue was taken to detect the levels of PLEKHH2 and SMAD7 proteins captured by Hic-5 antibody.

[0208] Consistent with the previous research results of this application, PLEKHH2 protein was significantly reduced in the lung tissue of rats in the WT+MCT group, and was reduced more in rats in the P-KO+MCT group. Correspondingly, PLEKHH2 protein bound to Hic-5 was the highest in WT, significantly reduced in WT+MCT, and reduced more in P-KO+MCT. In contrast, the binding of SMAD7 protein to Hic-5 was significantly increased in WT+MCT compared with WT, and increased more in P-KO+MCT ( Fig. 22 ).

[0209] (2) Chronic hypoxia group

[0210] We set up three groups of rats: 1) wild-type rats (WT) fed with normoxia, 2) wild-type rats after chronic hypoxia (10% oxygen concentration) for three weeks (WT+Hypo); 3) PLEKHH2 gene knockout heterozygous rats after chronic hypoxia (10% oxygen concentration) for three weeks (P-KO+Hypo). Total protein in lung tissue was taken to detect the levels of PLEKHH2 and SMAD7 proteins captured by Hic-5 antibody.

[0211] Consistent with the results of the MCT group, PLEKHH2 protein was significantly reduced in the lung tissue of rats in the WT+Hypo group and was more reduced in rats in the P-KO+Hypo group. Correspondingly, the PLEKHH2 protein binding to Hic-5 was the highest in WT, significantly reduced in WT+Hypo, and more reduced in P-KO+Hypo. In contrast, the binding of SMAD7 protein to Hic-5 increased in WT+Hypo compared with WT, and increased extremely significantly in P-KO+Hypo ( Fig.23 ).

[0212] Therefore, we confirmed through two animal models of pulmonary hypertension that the binding of PLEKHH2 and SMAD7 proteins to Hic-5 protein in rat lung tissue is significantly negatively correlated, and there is an obvious competitive relationship between the two. Reduced expression of PLEKHH2 will promote the binding of Hic-5 and SMAD7 and reduce free SMAD7 protein. This molecular mechanism is consistent with our previous research results---knockout of the PLEKHH2 gene aggravates the phenotype of the animal model of pulmonary hypertension, suggesting that the loss of balance between PLEKHH2-Hic-5-SMAD7 is an important mechanism for the occurrence and development of pulmonary hypertension.

[0213] Example 15: Elevated PLEKHH2 expression reduces Hic-5 binding to SMAD7 in the setting of pulmonary hypertension

[0214] Previous work has shown that reduced PLEKHH2 protein expression will promote more binding of Hic-5 and SMAD7. So, can supplementing PLEKHH2 inhibit the binding of Hic-5 and SMAD7 at the in vivo level? We constructed two pulmonary hypertension rat models using MCT and Sugen+hypoxia, respectively, and increased the gene expression in lung tissue by tracheal spray of PLEKHH2 adenovirus. Three weeks later, rat lung tissue was taken and the binding of PLEKHH2 and SMAD7 to Hic-5 was detected by Co-IP experiment.

[0215] (1) Rats in MCT group

[0216] We obtained lung tissues from three groups of rats: 1) wild-type rats (WT) injected with normal saline, 2) wild-type rats injected with MCT (50 mg / kg) 4 weeks later (WT+MCT); 3) on the day of MCT injection, PLEKHH2 gene adenovirus was first administered to rats via tracheal spray to upregulate PLEKHH2 gene expression, PLEKHH2 gene adenovirus was administered for the second time at 2 weeks, and the experiment was terminated at 4 weeks (Ad-P+MCT).

[0217] like Fig.24 As shown in the figure, the PLEKHH2 protein in rats in the WT+MCT disease group was significantly reduced, and the binding of Hic-5 to SMAD7 was significantly enhanced. When the PLEKHH2 protein was significantly increased by adenovirus, the binding level of Hic-5 to SMAD7 was reduced to the normal control level.

[0218] (2) Rats in Sugen+hypoxia group

[0219] We collected lung tissues from three groups of rats: 1) wild-type rats injected with normal saline and fed with normoxia for 5 weeks (WT); 2) wild-type rats injected subcutaneously with Su-5416 (20 mg / kg) and subjected to hypoxia (10% oxygen concentration) for 3 weeks and reoxygenation for 2 weeks to construct a PAH rat model group (WT+SuHx); 3) on the day of subcutaneous injection of Su-5416, the PLEKHH2 gene adenovirus was first administered to the rats via tracheal spray to upregulate PLEKHH2 gene expression, and the PLEKHH2 gene adenovirus was administered for the second time at 3 weeks, and the experiment was terminated at 5 weeks (Ad-P+SuHx).

[0220] like Fig.25 As shown in the figure, the PLEKHH2 protein in the WT+SuHx disease group rats was significantly reduced, and the binding of Hic-5 to SMAD7 was significantly enhanced. When the PLEKHH2 protein was significantly increased by adenovirus, the binding level of Hic-5 to SMAD7 was reduced again to close to the normal control level.

[0221] Therefore, we confirmed through two animal models of pulmonary hypertension that exogenous supplementation of PLEKHH2 protein will significantly reduce the binding of Hic-5 and SMAD7 and increase free SMAD7 protein in the case of pulmonary hypertension. This molecular mechanism is consistent with our previous research results---supplementation of PLEKHH2 gene can prevent or treat the phenotype of animal models of pulmonary hypertension, suggesting that restoring the balance between PLEKHH2-Hic-5-SMAD7 is an important strategy for treating or preventing pulmonary hypertension.

[0222] Example 16 PLEKHH2 prevents pulmonary hypertension by inhibiting SMAD2 / 3 hyperphosphorylation

[0223] As mentioned above, SMAD7 is an important inhibitor of SMAD2 / 3 activity. To confirm whether the SMAD7 protein released after PLEKHH2 competitively binds to Hic-5 is active, we used the lung tissue of the MCT group rats in the previous example to detect the expression of PLEKHH2 protein and the phosphorylation of SMAD2 / 3. Fig.26 As shown in the figure, after MCT stimulation, PLEKHH2 was significantly reduced, the total protein of SMAD2 / 3 was significantly reduced, and the phosphorylated SMAD2 / 3 was significantly increased. After high expression of PLEKHH2 by adenovirus, the total protein of SMAD2 / 3 was restored to the level of wild-type rats, and the phosphorylation level was significantly reduced.

[0224] We found for the first time that PLEKHH2 and SMAD7 competitively bind to Hic-5 protein in lung tissue. Under the pathological condition of pulmonary hypertension, PLEKHH2 protein mutates or its expression level decreases, and Hic-5 captures more SMAD7, preventing SMAD7 from inhibiting SMAD2 / 3 activity, thereby enhancing the activity of the SAMD2 / 3 signaling pathway, promoting excessive proliferation of endothelial cells, accelerating the phenotype transition of endothelial cells to mesenchymal cells, and ultimately leading to pulmonary hypertension. Upregulating PLEKHH2 expression can prevent Hic-5 from binding to SMAD7, allowing more SMAD7 to be released into the cytoplasm, inhibiting SMAD2 / 3 phosphorylation, and thus treating pulmonary hypertension.

[0225] Based on the previous research results, this project further clarified the molecular mechanism of PLEKHH2 in protecting pulmonary vascular remodeling, and proposed and verified several new ideas for the treatment of pulmonary hypertension:

[0226] (1) Our results indicate that Hic-5 is highly expressed in pulmonary hypertension and captures more SMAD7 protein, preventing it from inhibiting the function of SMAD2 / 3. Therefore, degradation of Hic-5 is a potential strategy for the treatment of pulmonary hypertension.

[0227] (2) Designing small molecule compounds that mimic the binding site of Hic-5 and PLEKHH2 and reduce the binding of Hic-5 and SMAD7 will be the research and development direction of new drugs.

[0228] In addition, the present invention has experimentally confirmed that the above-mentioned small molecule compound that inhibits the binding of Hic-5 and SMAD7 can be used for the effective treatment of pulmonary arterial hypertension.

[0229] The description of the above embodiments is only used to understand the method and core idea of ​​the present invention. It should be pointed out that, for those skilled in the art, several improvements and modifications can be made to the present invention without departing from the principle of the present invention, and these improvements and modifications will also fall within the scope of protection of the claims of the present invention.

Claims

1. Use of an agent that inhibits the binding of Hic-5 to SMAD7 and / or an agent that inhibits Hic-5 in the preparation of a drug for preventing, treating, alleviating and / or improving pulmonary hypertension.

2. The use according to claim 1, characterized in that: The reagents include small molecule compounds, polypeptides, peptide mimetics, nucleic acid molecules, proteins, antibodies, antibody mimetics, fusion proteins, protein analogs, gene delivery vectors, protein delivery vectors, aptamers, shRNA, siRNA, miRNA, antisense nucleic acids, CRISPR gene editing reagents and / or any combination thereof targeting the binding site of Hic-5 and SMAD7 and / or targeting Hic-5; Optionally, the Hic-5 and SMAD7 binding site is the LIM3 domain of Hic-5; Optionally, the agent is capable of competitively binding with SMAD7 to the LIM3 domain of Hic-5; Optionally, the reagent includes PLEKHH2 and / or a PLEKHH2 promoter; Optionally, the PLEKHH2 and / or PLEKHH2 promoter includes PLEKHH2 gene, PLEKHH2 mRNA, PLEKHH2 cDNA, PLEKHH2 protein, peptide segment of PLEKHH2 protein, analog of PLEKHH2 protein, active fragment of any of the foregoing, vector expressing PLEKHH2, nanoparticles carrying PLEKHH2 gene, viral vector carrying PLEKHH2 gene, PEG-modified protein encapsulating PLEKHH2 gene or protein, protein microspheres encapsulating PLEKHH2 gene or protein, liposomes encapsulating PLEKHH2 gene or protein, extracellular vesicles encapsulating PLEKHH2 gene or protein and / or any combination thereof; Optionally, the PLEKHH2 and / or PLEKHH2 promoter prevents, treats, alleviates and / or improves pulmonary arterial hypertension by inhibiting SMAD2 / 3 hyperphosphorylation.

3. Use of PLEKHH2 and / or a PLEKHH2 promoter in the preparation of a drug for preventing, treating, alleviating and / or improving pulmonary hypertension.

4. The use according to claim 3, characterized in that: The PLEKHH2 includes PLEKHH2 gene, PLEKHH2 mRNA, PLEKHH2 cDNA, PLEKHH2 protein, active fragments of any of the foregoing, and / or any combination thereof; Optionally, the PLEKHH2 promoter includes a substance that increases the level of PLEKHH2, a substance that enhances the activity of PLEKHH2, a substance that delays the metabolism of PLEKHH2, and / or any combination thereof; Optionally, the PLEKHH2 promoter includes a natural purified substance, a modified natural purified substance, a semi-synthetic substance and / or a chemically synthesized substance; Optionally, the PLEKHH2 promoter includes PLEKHH2 protein, a peptide segment of PLEKHH2 protein, an analog of PLEKHH2 protein, a vector expressing PLEKHH2, nanoparticles carrying PLEKHH2 gene, a viral vector carrying PLEKHH2 gene, a PEG-modified protein encapsulating PLEKHH2 gene or protein, a protein microsphere encapsulating PLEKHH2 gene or protein, a liposome encapsulating PLEKHH2 gene or protein, an extracellular vesicle encapsulating PLEKHH2 gene or protein, and / or any combination thereof; Optionally, the PLEKHH2 and / or PLEKHH2 promoter can reduce right ventricular systolic pressure, alleviate right ventricular hypertrophy, increase tricuspid annular systolic displacement, and alleviate pulmonary artery vascular remodeling.

5. Any of the following products, characterized in that: The products include: (1) A pharmaceutical composition for preventing, treating, alleviating and / or improving pulmonary arterial hypertension, the pharmaceutical composition comprising an agent for inhibiting the binding of Hic-5 to SMAD7 and / or an agent for inhibiting Hic-5 as described in claim 1 or 2, and / or PLEKHH2 and / or a PLEKHH2 promoter as described in claim 3 or 4; (2) A pharmaceutical preparation for preventing, treating, alleviating and / or improving pulmonary hypertension, comprising the pharmaceutical composition.

6. The product according to claim 5, characterized in that The pharmaceutical composition may also contain other drugs for preventing, treating, alleviating and / or improving pulmonary hypertension; Optionally, the drug includes a calcium channel blocker, a prostacyclin drug, an endothelin receptor antagonist, a phosphodiesterase-5 inhibitor and / or a guanylate cyclase agonist; Optionally, the pharmaceutical composition may further comprise a pharmaceutically acceptable carrier and / or excipient; Optionally, the dosage form of the pharmaceutical preparation includes injection, lyophilized powder, solution, tablet, capsule, granule, ointment, cream, gel, suspension, oral solution, controlled release dosage form, nanocrystal preparation, microemulsion and / or solid dispersion.

7. Any of the following applications, characterized in that: The applications include: (1) Application of the LIM3 domain of Hic-5 in screening candidate drugs for preventing, treating, alleviating and / or improving pulmonary arterial hypertension; (2) Use of PLEKHH2 and / or Hic-5 in screening candidate drugs for preventing, treating, alleviating and / or improving pulmonary arterial hypertension; (3) Application of Hic-5 and / or SMAD7 in screening candidate drugs for preventing, treating, alleviating and / or improving pulmonary arterial hypertension; (4) Use of SMAD7 in the preparation of a drug for preventing, treating, alleviating and / or improving pulmonary hypertension; (5) Use of a reagent for detecting the expression level of PLEKHH2 in a sample in the preparation of a product for diagnosing and / or assisting in the diagnosis of pulmonary arterial hypertension.

8. The use according to claim 7, characterized in that: The reagents include a reagent for detecting the expression level of PLEKHH2 mRNA in a sample and a reagent for detecting the expression level of PLEKHH2 protein in a sample; Optionally, the reagent for detecting the expression level of PLEKHH2 mRNA in a sample includes primers that specifically amplify PLEKHH2 and / or probes that specifically recognize PLEKHH2; Optionally, the reagent for detecting the expression level of PLEKHH2 protein in a sample includes a binding agent that specifically binds to a protein encoded by PLEKHH2; Optionally, the binding agent includes an antibody, a functional fragment of an antibody, an agglutinating agent, a receptor and / or a coupled antibody that specifically binds to a protein encoded by PLEKHH2.

9. Any of the following methods, characterized in that: The method comprises: (1) A method for screening candidate drugs for preventing, treating, alleviating and / or improving pulmonary hypertension, the method comprising the following steps: (a) treating a system expressing or containing the PLEKHH2 gene with a test substance; (b) detecting the expression of the PLEKHH2 gene in the system; (c) selecting a test substance that can increase the expression level of the PLEKHH2 gene as a candidate drug; (2) A method for screening candidate drugs for preventing, treating, alleviating and / or improving pulmonary hypertension based on the LIM3 domain of Hic-5, the method comprising the following steps: screening an agent capable of binding to the LIM3 domain of Hic-5 as a candidate drug; (3) A method for screening candidate drugs for preventing, treating, alleviating and / or improving pulmonary hypertension based on PLEKHH2 and / or Hic-5, the method comprising the following steps: simulating the binding site of Hic-5 and PLEKHH2, designing and / or screening agents that can bind to the binding site as candidate drugs; (4) A method for screening candidate drugs for preventing, treating, alleviating and / or improving pulmonary hypertension based on Hic-5 and / or SMAD7, the method comprising the following steps: simulating the binding site of Hic-5 and SMAD7, and designing and / or screening agents that can bind to the binding site as candidate drugs; Optionally, the system comprises a cell system, a subcellular system, a solution system, a tissue system, an organ system and / or an animal system; Optionally, the substance to be tested includes a substance that increases the level of PLEKHH2, a substance that enhances the activity of PLEKHH2, a substance that delays the metabolism of PLEKHH2, and / or any combination thereof; Optionally, the reagent includes small molecule compounds, polypeptides, peptide mimetics, nucleic acid molecules, proteins, antibodies, antibody mimetics, fusion proteins, protein analogs, gene delivery vectors, protein delivery vectors, aptamers, shRNA, siRNA, miRNA, antisense nucleic acids, CRISPR gene editing reagents and / or any combination thereof targeting the Hic-5 and SMAD7 binding sites and / or targeting Hic-5.

10. Any of the following products, characterized in that: The products include: (1) A product for diagnosing and / or assisting in the diagnosis of pulmonary hypertension, the product comprising the reagent according to claim 7 or 8; (2) A system / device for diagnosing and / or assisting in the diagnosis of pulmonary hypertension, the system / device comprising a processor, an input module, and an output module; The processor is used to perform logical operations on the input information using bioinformatics methods; the input module is used to input the expression level of PLEKHH2 in the subject sample, and contains a computer-readable medium of instructions, which, when executed by the processor, executes an algorithm on the input expression level of PLEKHH2; the output module is used to output whether the subject suffers from pulmonary hypertension or the risk of suffering from pulmonary hypertension; Optionally, the product further comprises a reagent for detecting the expression level of PLEKHH2 in a sample by sequencing technology, nucleic acid hybridization technology, nucleic acid amplification technology and / or protein immunoassay technology; Optionally, the product includes a kit, a chip and / or a test strip.

Citation Information

Patent Citations

  • PTGIS gene mutation related to pulmonary hypertension and application thereof

    CN107602690A

  • Treatment of SMC mediated disease

    CN111655724A

  • Modulation of epithelial cell differentiation, maintenance and / or function through t cell action, and markers and methods of use thereof

    US20210040442A1

Cited By

  • Application of inhibiting combination of Hic-5 and SMAD7 and / or inhibiting Hic-5 in pulmonary arterial hypertension treatment

    CN121466294A